Professor Numa Dancause Joins Panaxium Therapy Development Team as Scientific Advisor and Pre-Clinical Collaborator

World-leader in cortical motor control research and Université de Montréal Professor is an expert in premotor cortex function and cortical plasticity following brain injury.

Aix-en-Provence, FRANCE, and Toronto, CANADA, December 6, 2021. — Bioelectronic medicine company Panaxium SAS today announced that Université de Montréal Professor Numa Dancause, PhD will join the company as Scientific Advisor.

Bioelectronic medicine is an emerging scientific field that aims to tackle many debilitating and degenerative medical conditions and injuries by leveraging the newest bioelectronics and building imperceptible devices at the microscale dimensions of individual cells. There is significant potential to treat a wide range of diseases and conditions such as stroke, traumatic brain injuries, Parkinson’s, Alzheimer’s, and peripheral nerve damage.

Dr. Dancause is a world-leading expert in the study of motor control, premotor cortex function and cortical plasticity following brain injury. In his research, he uses multiple electrophysiological and neuroanatomical techniques in combination with behavioral analysis in many diverse animal models. Dr. Dancause will lend his expertise to refine the design of Panaxium’s pre-clinical and clinical studies, and will conduct groundbreaking collaborative work in his lab using Panaxium’s proprietary devices.

Dr. Dancause joined Université de Montréal in 2009 after training with some of the world’s foremost experts on motor control and neural plasticity. He completed postdoctoral training with Dr. Roger Lemon at University College London (UK) and Dr. Marc Schieber at the University of Rochester Medical Center, and previously completed his PhD under the guidance of Dr. Randolph Nudo at the Kansas University Medical Center. Dr. Dancause was the first recipient of the Power Corporation Chair of Physiology and has received Canada Institutes of Health Research (CIHR) New Investigator award. He is now a Senior Investigator for the Fonds de la recherche en santé du Québec (FRQS).

“We are thrilled to have Professor Dancause lending his expertise to our team and advising us in our preclinical development,” says Dr. Brad Schmidt, Panaxium CEO. “We couldn’t have a more appropriate expert in neuro-electrophysiology aiding in the development of neuro-recovery therapies.”

About Panaxium

Founded in 2016, Panaxium is a rapidly growing bioelectronic medicine company aiming to give every neuro-injured patient a chance of returning to normalcy. The company has offices and labs in Aix-en-Provence, France, and Toronto, Canada, and is comprised of an international multidisciplinary team of scientists and engineers with expertise in organic bioelectronics, chemistry, materials science, machine learning, neuroscience, and microtechnology system design. Together with their Scientific and Clinical Advisors at leading academic and clinical institutions around the world they are solving some of the most difficult and important problems in medicine.  

For more information, please visit